| Literature DB >> 28962035 |
S F Rinaldi1, S Makieva1, P T Saunders2, A G Rossi2, J E Norman1.
Abstract
STUDY QUESTION: Is labour, both at term and preterm, associated with alterations in decidual lymphocyte densities and widespread changes to the decidual transcriptome? SUMMARY ANSWER: The onset of parturition, both at term and preterm, is associated with widespread gene expression changes in the decidua, many of which are related to inflammatory signalling, but is not associated with changes in the number of any of the decidual lymphocyte populations examined. WHAT IS KNOWN ALREADY: Given its location, directly at the maternal-foetal interface, the decidua is likely to play a pivotal role in the onset of parturition, however, the molecular events occurring in the decidua in association with the onset of labour, both at term and preterm, remain relatively poorly defined. Using flow cytometry and microarray analysis, the present study aimed to investigate changes to the immune cell milieu of the decidua in association with the onset of parturition and define the decidual gene signature associated with term and preterm labour (PTL). STUDY DESIGN, SIZE, DURATION: This study used decidual samples collected from 36 women across four clinical groups: term (38-42 weeks of gestation) not in labour, TNL; term in labour, TL; preterm (<35 weeks of gestation)not in labour, PTNL; and preterm in labour, PTL. PARTICIPANTS/MATERIALS, SETTING,Entities:
Keywords: decidua; immune; inflammation; microarray; parturition; preterm labour
Mesh:
Substances:
Year: 2017 PMID: 28962035 PMCID: PMC5909855 DOI: 10.1093/molehr/gax038
Source DB: PubMed Journal: Mol Hum Reprod ISSN: 1360-9947 Impact factor: 4.025
Demographic and clinical characteristics of the study groupsa.
| TNL ( | TL ( | PTNL ( | PTL ( | |
|---|---|---|---|---|
| Maternal age (year) | 34 (30–43) | 26 (22–40) | 34 (18–39) | 30 (16–39) |
| Parityb | 1 (0–2) | 0 (0–1) | 0 (0–2) | 0 (0–3) |
| BMI (kg/m2)c | 22.7 (19.9–28.1) | 27.1 (21.0–28.7) | 24.4 (22.1–26.2) | 24.8 (19.5–30.0) |
| Gestation at delivery (week) | 39.3 (39.0–41.0) | 40.1 (38.2–41.1) | 32.4 (29.0–34.4)*## | 30.4 (24.0–34.6)**#### |
| Indication for caesarean section ( | ||||
| Foetal distress | 0 | 2 | 0 | 3 |
| Failure to progress | 0 | 3 | 0 | 0 |
| Breech presentation | 2 | 0 | 0 | 2 |
| Obstetric history | 6 | 0 | 0 | 0 |
| IUGR | 0 | 0 | 4 | 0 |
| Pre-eclampsia | 0 | 0 | 2 | 0 |
| Other or missing | 3 | 3 | 1 | 5 |
| Foetal membrane rupture | ||||
| Spontaneous | 0 | 5 | 0 | 2 |
| Artificial | 0 | 3 | 0 | 2 |
| PPROM | 0 | 0 | 0 | 6 |
| None or missing | 11 | 0 | 7 | 0 |
| Evidence of chorioamnionitis: | 0 (0%) | 5 (50%) | ||
| Evidence of placental abruption: | 0 (0%) | 1 (10%) | ||
aThe numbers are median and range unless otherwise indicated.
bParity data were missing from one patient in the PTL group.
cBMI at booking to antenatal care. Due to patient transfer, BMI was not available for three PTNL patients and three PTL patients.
dChorioamnionitis status from available pathology reports for preterm patients. Pathology reports were not available for two PTL patients.
ePlacental abruption confirmed from available pathology reports from preterm patients. Pathology reports were not available for two PTL patients.
*P < 0.05, **P < 0.01 versus TNL; ##P < 0.01, ####P < 0.0001 versus TL; Kruskal–Wallis with post hoc Dunn test.
Figure 1Decidual immune cell population analysis in term and PTL. Flow cytometric analysis of isolated decidual mononuclear cells from four patient groups: TNL (n = 8), TL (n = 7), PTNL (n = 5) and PTL (n = 5). Cells were stained with antibodies raised against the following antigens: CD45, CD3, CD56, CD19, CD4 and CD8. (A) Gating strategy. Lymphocytes were gated based on their forward light scatter (FSC) and side light scatter (SSC), doublet cells were removed and live cells were selected based on exclusion of DAPI. Individual cell populations were then identified based on antibody staining. (B) Proportion of CD45+ lymphocytes out of all live cells within lymphocyte gate. (C) Proportion of CD3−CD56+ NK cells within the CD45+ lymphocyte gate. (D) Proportion of CD19+ B cells within the CD45+ lymphocyte gate. (E) Proportion of CD3+ T cells within the CD45+ lymphocyte gate. (F) Proportion of CD4+ T cells within the CD3+ T cell gate. (G) Proportion of CD8+ T cells within the CD3+ T cell gate. Data presented as mean ± SEM. Data were analysed by Kruskal–Wallis but no significant differences were found. PTL, preterm labour.
Figure 2Decidual iNKT cells and CD1d in term and PTL. The presence of a decidual iNKT cell population was examined using flow cytometry in samples from our four patient groups: TNL (n = 8), TL (n = 7), PTNL (n = 5) and PTL (n = 5). (A) Decidual iNKT cells were gated based on their expression of CD3 and TCRVα24 Jα18. (B) Proportion of iNKT cells within the CD3+ gate. Decidual expression of CD1d was examined at the mRNA and protein level by qRT-PCR and western blotting, respectively. (C) Decidual CD1D mRNA expression [TNL (n = 11); TL (n = 8), PTNL (n = 7), PTL (n = 10)]. (D) Decidual CD1d protein expression (n = 7 in each group). Data presented as mean ± SEM. QRT-PCR data analysed by one-way ANOVA followed by Newman–Keuls post hoc test; flow cytometry and western blot data analysed by Kruskal–Wallis followed by Dunn post hoc test. *P < 0.05. iNKT, invariant natural killer.
Top 10 DEGs.
| Comparison | Symbol | Description | Fold change | |
|---|---|---|---|---|
| TL vs TNL | tumour necrosis factor, alpha-induced protein 3 | 2.716 | 1.40E–04 | |
| immediate early response 3 | 2.68 | 2.37E–03 | ||
| interleukin 6 | 2.657 | 8.79E–03 | ||
| prostaglandin-endoperoxide synthase 2 | 2.474 | 2.15E–03 | ||
| activating transcription factor 3 | 2.31 | 6.30E–03 | ||
| pleckstrin homology-like domain, family A, member 1 | 2.147 | 3.98E–03 | ||
| dual specificity phosphatase 5 | 2.066 | 3.64E–03 | ||
| nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha | 1.988 | 8.04E–04 | ||
| zinc finger CCCH-type containing 12 A | 1.905 | 3.84E–03 | ||
| DNA-damage-inducible transcript 4 | 1.824 | 4.79E–03 | ||
| matrix metallopeptidase 7 (matrilysin, uterine) | −2.387 | 1.84E–03 | ||
| zinc finger CCCH-type, antiviral 1 | −1.564 | 1.51E–05 | ||
| collagen, type VI, alpha 3 | −1.538 | 4.49E–03 | ||
| cold inducible RNA binding protein | −1.456 | 1.88E–03 | ||
| nidogen 1 | −1.396 | 7.91E–03 | ||
| cytochrome b561 family, member D1 | −1.394 | 2.64E–03 | ||
| calsyntenin 1 | −1.355 | 9.51E–03 | ||
| phospholysine phosphohistidine inorganic pyrophosphate phosphatase | −1.338 | 2.94E–03 | ||
| RAB22A, member RAS oncogene family | −1.327 | 9.02E–04 | ||
| coiled-coil domain containing 106 | −1.303 | 6.30E–03 | ||
| TL vs PTL | FBJ murine osteosarcoma viral oncogene homologue B | 2.538 | 9.45E–03 | |
| follistatin | 2.325 | 3.96E–03 | ||
| hes family bHLH transcription factor 4 | 1.691 | 9.09E–04 | ||
| Kruppel-like factor 4 (gut) | 1.563 | 9.62E–03 | ||
| SAM and SH3 domain containing 1 | 1.493 | 8.10E–03 | ||
| harakiri, BCL2 interacting protein | 1.492 | 9.84E–03 | ||
| neural precursor cell expressed, developmentally down-regulated 9 | 1.489 | 5.24E–03 | ||
| ELM2 and Myb/SANT-like domain containing 1 | 1.44 | 2.50E–03 | ||
| forkhead box C1 | 1.418 | 4.11E–03 | ||
| cyclin B1 interacting protein 1, E3 ubiquitin protein ligase | 1.414 | 6.07E–03 | ||
| fibrinogen alpha chain | −4.108 | 6.28E–03 | ||
| fibrinogen gamma chain | −3.688 | 5.88E–04 | ||
| fibrinogen beta chain | −2.753 | 2.53E–03 | ||
| plasminogen activator, tissue | −2.235 | 5.73E–03 | ||
| macrophage receptor with collagenous structure | −2.087 | 4.03E–03 | ||
| leucocyte immunoglobulin-like receptor, subfamily A (without TM domain), member 3 | −1.945 | 9.45E–03 | ||
| nuclear receptor subfamily 1, group H, member 3 | −1.769 | 8.67E–03 | ||
| potassium channel, subfamily K, member 4 | −1.75 | 1.95E–03 | ||
| tumour necrosis factor receptor superfamily, member 8 | −1.72 | 1.53E–03 | ||
| tryptophanyl-tRNA synthetase | −1.712 | 9.12E–03 | ||
| PTL vs PTNL | chemokine (C-X-C motif) ligand 8 | 5.441 | 2.49E–03 | |
| cell migration inducing protein, hyaluronan binding | 3.338 | 6.97E–03 | ||
| S100 calcium binding protein A8 | 3.193 | 1.02E–03 | ||
| fibrinogen gamma chain | 3.023 | 3.76E–03 | ||
| superoxide dismutase 2, mitochondrial | 2.89 | 2.04E–03 | ||
| fibrinogen beta chain | 2.784 | 3.08E–03 | ||
| nicotinamide phosphoribosyltransferase | 2.742 | 1.03E–03 | ||
| fibrinogen gamma chain | 2.687 | 9.45E–04 | ||
| S100 calcium binding protein A9 | 2.547 | 9.93E–04 | ||
| aquaporin 9 | 2.528 | 3.60E–03 | ||
| FBJ murine osteosarcoma viral oncogene homologue B | −2.652 | 8.73E–03 | ||
| tumour-associated calcium signal transducer 2 | −2.334 | 9.47E–03 | ||
| mannosyl (beta-1,4-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase | −1.702 | 2.04E–03 | ||
| SAM and SH3 domain containing 1 | −1.536 | 6.36E–03 | ||
| cytochrome b561 family, member D1 | −1.467 | 1.96E–03 | ||
| family with sequence similarity 53, member B | −1.448 | 5.53E–03 | ||
| crystallin, zeta (quinone reductase) | −1.438 | 9.11E–03 | ||
| chromosome 22 open reading frame 29 | −1.436 | 2.44E–03 | ||
| zinc fingers and homeoboxes 3 | −1.428 | 2.39E–04 | ||
| V-set domain containing T cell activation inhibitor 1 | −1.412 | 1.12E–03 |
DEG, differentially expressed gene.
Figure 3Sample–sample network graph of microarray data. Normalized expression data for the top up-and down-regulated genes (P < 0.05, fold change ≥ 1.2) identified by microarray analysis were visualized using BioLayout Express3D. Each node represents a different patient sample and edges are coloured to reflect the Pearson correlation that they represent. Red edges indicate high correlation, and blue edges represent low correlation. The same data set is used for each graph. (A) unbiased MCL cluster (MCLi = 20). (B) Nodes are coloured by gestation and labour status into our four sample groups: TNL (n = 11), TL (n = 9), PTNL (n = 7) and PTL (n = 8).
Figure 4QRT-PCR validations of gene expression changes in TL decidua samples. Decidual expression of selected genes identified as significantly elevated in TL in the microarray analysis was examined across our four sample groups by qRT-PCR [TNL (n = 11), TL (n = 9), PTNL (n = 7) and PTL (n = 10)]. (A) IL-6 expression, (B) PTGS2 expression, (C) IER3 expression, (D) TNFAIP3 expression and (E) ATF3 expression. Data are presented as mean fold change ± SEM. Data were analysed by one-way ANOVA followed by Tukey post hoc test. *P < 0.05, ***P < 0.001.
Figure 5QRT-PCR validations of gene expression changes in PTL decidua samples. Decidual gene expression of selected genes identified as significantly elevated in PTL samples in the microarray analysis was examined across our four sample groups by qRT-PCR [TNL (n = 11), TL (n = 9), PTNL (n = 7), PTL (n = 10)]. (A) CXCL8 expression, (B) MARCO expression, (C) LILRA3 expression, (D) FGA expression, (E) FGB expression, (F) FGG expression, (G) PLAT expression and (H) PLAU expression. Data are presented as mean fold change ± SEM. Data were analysed by one-way ANOVA followed by Tukey post hoc test. *P < 0.05, **P < 0.01.